findmyKOL

Tarek Sousou, MD

Basic profile

University of Rochester

ORCIDNone on fileNPI
RegionEast Syracuse, NY · NortheastSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2011Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Tarek Sousou is an Oncology physician affiliated with University of Rochester. OpenAlex indexes 10 publications with 388 citations (h-index 6).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
10publications

Distinct works indexed by OpenAlex.

388citations

Total citations across indexed works.

6h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
11companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

5008 Brittonfield Pkwy
East Syracuse, NY 13057

Telephone

315-472-7504

Registry record last updated 3 Aug 2018.

View the NPPES registry record

Industry payments

11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    44.7%
    PD-1 inhibitor20.1%
    Pembrolizumab55%Nivolumab45%
    Part B, office-administered46 patients
    Nucleoside Metabolic Inhibitor6.5%
    Azacitidine91%Fluorouracil7%Gemcitabine hydrochloride2%
    Part B, office-administered37 patients

    + 11 more classes in this area

  • Blood & clotting

    30.6%
    Iron, parenteral preparations19.8%
    Ferric carboxymaltose100%
    Part B, office-administered44 patients
    Erythropoiesis-stimulating Agent10.8%
    Darbepoetin alfa97%Epoetin alfa3%
    Part B, office-administered39 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    11.3%
    Substance P/Neurokinin-1 Receptor Antagonist8.4%
    Aprepitant100%
    Part B, office-administered65 patients
    Serotonin-3 Receptor Antagonist1.5%
    Palonosetron hcl82%Granisetron hydrochloride15%Ondansetron hydrochloride4%
    Part B, office-administered103 patients

    + 3 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”